Like scientific papers, oral presentations at a conference or internal seminar are for sharing your research work with other scientists. They, too, must convince the audience that the research ...
Oral communication describes any type of interaction that makes use of spoken words, and it is a vital, integral part of the business world, especially in an era dubbed the information age. “The ...
Oral presentations are commonplace in the business world. Individuals who work in small companies may be especially busy giving presentations as sharing information is vital in a small company. There ...
PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing ...
Informal Providers—Ground Realities in South Asian Association for Regional Cooperation Nations: Toward Better Cancer Primary Care: A Narrative Review Hidden oral cancer sites and residence in ...
NEW YORK, April 28, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare ...
AURORA, Colo., Oct. 1, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, today announced that a human ...
GENOA, Italy--(BUSINESS WIRE)--IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the ...
4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025 IDE275 (GSK959) has demonstrated a potential best ...
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory ...
Oral presentations are a richer medium than written documents. They allow you to establish stronger contact with the audience and better convince them of your viewpoint through verbal and nonverbal ...
Arvinas will present Phase 3 VERITAC-2 trial results for vepdegestrant at ASCO 2025, evaluating its effectiveness in breast cancer treatment. Arvinas, Inc. announced that it will present the detailed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback